Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including follicular and mantl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Follicular Lymphoma
• Hairy Cell Leukemia
• Large B-cell Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Autologous CD22 CAR-T cells (CD22-directed CAR-T cells)

Snippet

Sponsor: Stanford University | Conditions: Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Status: RECRUITING